These results are contradict previous data from the literature suggesting that in prostatic carcinomas ANRIL overexpression was mainly accompanied by transcriptional inactivation of the p16-CDKN2A/p15-CDKN2B/p14-ARF locus via repressive action of the two polycomb complexes PRC2 and PRC1 [6]. This evidence concerns the gene CDKN2B-AS1 and prostate carcinoma.